New hope for AML patients who fail standard therapy: experimental combo trial launches
NCT ID NCT07505160
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new combination of drugs—lisafotoclax, decitabine, and homoharringtonine—in 35 adults with acute myeloid leukemia (AML) whose cancer did not respond to or could not tolerate the standard venetoclax/azacitidine regimen. The goal is to see if this new mix can shrink or eliminate the leukemia. Participants will receive the drugs in cycles and be followed for up to a year. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lisafotoclax (an experimental BCL-2 inhibitor) combined with decitabine and homoharringtonine
What this could lead to
If successful, this could offer a new treatment option for AML patients whose cancer no longer responds to standard venetoclax-based therapy.
What could go wrong
This is a small, early-phase trial with only 35 participants and no comparison group. The combination may cause serious side effects, and results may not apply to all AML patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••